To report trends of intravitreal corticosteroid use and explore the relationship between career experience, reported industry payments, and prescribing habits. Retrospective review of ophthalmologists who administered intravitreal dexamethasone implants (DEX) and triamcinolone acetonide (TA) injections between August 2013 to December 2017. A total of 1070 US ophthalmologists were reimbursed by Medicare for 522,804 DEX injections and 2.6 million TA injections. There was a significant positive trend in the number of DEX (P=.01), but not TA, injections per year. Mid- and late-career physicians performed significantly greater total injections on average compared to early-career physicians (both P<.001). Early-career physicians performed a greater proportion of DEX injections than late-career physicians (P=.006). Industry payments were positively associated with the proportion of DEX used and inversely correlated with the proportion of TA administered (P<.001). On multivariate analysis, years in practice, number of payments, and total value of payments were significantly associated with the number of DEX injections administered (all P<.001). From 2013 to 2017, the use of DEX increased while TA use remained stable. There was a positive association between DEX use and physician-industry interactions, which may be explained by seniority and experience. This study does not define a causal relationship. From 2013 to 2017, the use of DEX increased while TA use remained stable. There was a positive association between DEX use and physician-industry interactions, which may be explained by seniority and experience. This study does not define a causal relationship. To analyze the incidence, risk factors and time to onset of ocular hypertension (OHT) after intravitreal injections (IVI) of Dexamethasone implant (DEX-I) and to evaluate the long-term cumulative probability of intraocular pressure elevation. Eyes of patients having received at least one DEX-I IVI between October 2010 and February 2015 were included in the present study. OHT was defined as IOP > 25 mmHg and/or an increase of 10 mmHg over the follow-up period compared with baseline IOP. 494 eyes were studied in 410 patients. For a total of 1,371 IVI, the incidence of OHT was 32.6% in the study eyes with a mean follow-up period of 30 months (3-62.5) and a median follow-up of 29 months. Pressure-lowering treatment was introduced for 36.9% of eyes. Topical treatment alone was sufficient to manage OHT in 97%. Young age, male sex, uveitis and retinal vein occlusion (RVO), glaucoma treated with a double or triple-combination topical pressure-lowering medication were found to be risk factors for OHT. The incidence of OHT did not change with an increase in the number of IVI, and there was no cumulative effect, defining by an increase of the incidence of OHT in patients after repeated IVI (p=0.248). This study confirmed that OHT is of moderate incidence, transient, controlled by topical treatment and provides data on the long-term cumulative probability of IOP elevation in a large cohort of eyes treated with DEX-I IVI. Repeat injections of DEX-I neither increase nor decrease the risk of OHT. This study confirmed that OHT is of moderate incidence, transient, controlled by topical treatment and provides data on the long-term cumulative probability of IOP elevation in a large cohort of eyes treated with DEX-I IVI. Repeat injections of DEX-I neither increase nor decrease the risk of OHT. To determine the glycemic responses to cardiopulmonary exercise testing (CPET) in individuals with type 1 diabetes (T1D) and to explore the influence of starting blood glucose (BG) concentrations on subsequent CPET outcomes. This study was a retrospective, secondary analysis of pooled data from three randomised cross-over trials using identical CPET protocols. During cycling, cardiopulmonary variables were measured continuously, with BG and lactate values obtained minutely via capillary earlobe sampling. https://www.selleckchem.com/products/super-tdu.html Anaerobic threshold (AT) was determined using ventilatory parameters. Participants were split into (i) euglycemic ([Eu] >3.9 to ≤10.0 mmol.L, n=26) and (ii) hyperglycemic ([Hyper] >10.0 mmol.L, n=10) groups based on pre-exercise BG concentrations. Data were assessed via general linear modelling techniques and regression analyses. P values of ≤0.05 were accepted as significant. Data from thirty-six individuals with T1D (HbA1c; 7.3±1.1% [56.0±11.5 mmol.mol]) were included. BG remained equivalent to quent glycemic dynamics, it did potentiate alterations in various cardiac and metabolic responses to CPET 3) HbA1c was a significant factor in the determination of peak performance outcomes during CPET. Women who develop gestational hypertension have evidence of elevated muscle sympathetic nerve activity (MSNA) in early pregnancy which continues to rise following diagnosis. Exercise has been shown to play a preventative role in the development of gestational hypertension and has been shown to reduce resting and reflex MSNA in non-pregnant populations., We sought to investigate whether aerobic exercise impacted sympathetic regulation of blood pressure between the second and third trimester of pregnancy. We conducted a randomized controlled trial of structured aerobic exercise (n=31) compared to no intervention (control, n=28) beginning at 16-20 weeks and continuing until 34-36 weeks gestation (NCT02948439). Women in the exercise group were prescribed aerobic activity at 50-70% of their heart rate reserve, on 3-4 days per week for 25-40minutes with a 5-minute warm up and 5-minute cool down (i.e. up to 160 minutes total activity per week). At pre- and post-intervention assessments, data from ~10-minutes of quiet rest and a 3-minute cold pressor test (CPT) were analyzed to determine sympathetic nervous system activity and reactivity. MSNA was obtained in 51% of assessments. Resting MSNA BF and BI increased across gestation (main effect of gestational age, p=0.002). Neurovascular transduction (NVT) was blunted in the control group (p=0.024) but not in exercisers (p=0.873) at the post-intervention time-point. Lastly, MSNA reactivity during CPT by was not impacted by gestational age or exercise (p=0.790, interaction). These data show that exercise attenuates both the rise in MSNA and the blunting of NVT. This may partially explain the lower risk of developing gestational hypertension in women who are active during their pregnancies. These data show that exercise attenuates both the rise in MSNA and the blunting of NVT. This may partially explain the lower risk of developing gestational hypertension in women who are active during their pregnancies.